INTRODUCTION AND OBJECTIVES: WISQOL, the first validated, disease-specific measure of HRQoL in kidney stone patients is a psychometric health status instrument i.e. it records frequency and intensity of symptoms and behaviors related to urinary stone disease (USD). Alternatively, health utilities assess HRQoL on a 0-1 scale (0[ death and 1[perfect health), and are the preferred metric for use in healthcare economic valuation. We sought to establish the statistical relationship between WISQOL scores and SF-6D and EQ-5D derived utility scores in USD patients. Construct validity of the utility measures was also assessed.
METHODS: Consecutive adult USD patients, as well as young healthy controls without a history of USD were recruited. Each subject completed a health history survey, the SF-36 v2 and the EQ-5D questionnaires. USD patients additionally completed the WISQOL. SF-6D score was computed from 11 of the 36 items on the SF-36 v2 using validated, previously reported methodology.
Relationship between WISQOL and SF-6D / EQ-5D utility scores was examined using Pearson's correlation as well as multivariable regression with adjustment for baseline clinico-demographic characteristics. Utilities for USD patients vs. controls were compared using t-tests.
RESULTS: 91 patients and 78 controls were enrolled. SF-6D and EQ-5D utilities were significantly lower in patients compared with controls (Table 1) . For USD patients, SF-6D and EQ-5D utilities significantly correlated with WISQOL raw and subscale scores (Table 2) . On multivariable regression, 75.8% and 32.2% of the variance in SF-6D and EQ-5D utility scores respectively, was predicted by WISQOL raw score (p<0.0001 in each case).
CONCLUSIONS: WISQOL scores significantly correlated with, and had good predictive validity for the preference-based HRQoL scores in USD patients. SF-6D and EQ-5D utilities had excellent construct validity for USD. Our findings support these utilities as optimal preference-based HRQoL tools in USD. Results highlighted the need for comparative effectiveness research studies among patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Based on these results, we constructed a research design for a trial entitled Comparison of Intravesical therapy and Surgery as Treatment Options (CISTO). We sought input from individuals with bladder cancer and their caregivers with a survey distributed to the BCAN PSN to query attitudes about randomization, study design, and relevant patient-centered outcomes.
METHODS: We conducted a web-based survey of the 1,300-member BCAN PSN. Responses were collected between March 6, 2017, and April 6, 2017. The survey included questions about bladder cancer diagnosis and treatment history, willingness to participate in clinical trials with different study designs, and the relative importance of various outcomes.
RESULTS: A total of 291 individuals previously diagnosed with bladder cancer responded, 201 of whom reported having had NMIBC, and 104 of whom had experienced recurrent NMIBC after BCG treatment. Among all respondents and within the subgroup of patients who experienced recurrent NMIBC after BCG, only 11% reported being willing to consent to randomization for a study of radical cystectomy versus intravesical therapy. The majority (76%) indicated a strong preference to keep their bladders. Therefore, a prospective observational cohort study was selected as the highest quality, most feasible and inclusive study design. Respondents recommended that the most relevant domains with which to compare our two treatments were survival and QOL, ranked in order of: 1) overall survival, 2) risk of spread of the cancer to other parts of the body, 3) overall QOL, 4) impact of the treatments on their caregiver or loved one, 5) urinary QOL, and 6) the costs or financial distress these treatments can incur. These outcomes were included as primary and secondary endpoints in CISTO.
CONCLUSIONS: Patient input from the BCAN PSN informed the design of a patient-centered pragmatic trial for bladder cancer, which was Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1113
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